Moleculin reports 40% blinded CRc in MIRACLE trial; 35 subjects treated, unblinding on track for Q1 2026

Moleculin Biotech, Inc.

Preliminary blinded composite CR rate of 40% (30% CR, 10% CRh) in first 30 subjects; 67% above historical cytarabine CR.
35 subjects treated to date with 11 in screening; targeting first unblinding at 45 subjects, on track for Q1 2026 treatment milestone.
Roughly 35% of treated subjects are venetoclax regimen failures, a challenging population with high unmet need.
Continued absence of cardiotoxicity cited; Annamycin holds FDA Fast Track and Orphan Drug Designation for R/R AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.